Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) and Krystal Biotech (NASDAQ:KRYS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.
Volatility and Risk
Palvella Therapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Profitability
This table compares Palvella Therapeutics and Krystal Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palvella Therapeutics | N/A | -47.84% | -38.33% |
| Krystal Biotech | 54.82% | 19.34% | 17.65% |
Insider & Institutional Ownership
Valuation & Earnings
This table compares Palvella Therapeutics and Krystal Biotech”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palvella Therapeutics | $42.81 million | 51.06 | -$41.72 million | ($4.83) | -31.41 |
| Krystal Biotech | $389.13 million | 25.87 | $204.83 million | $7.98 | 42.61 |
Krystal Biotech has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for Palvella Therapeutics and Krystal Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palvella Therapeutics | 1 | 0 | 12 | 2 | 3.00 |
| Krystal Biotech | 0 | 2 | 10 | 1 | 2.92 |
Palvella Therapeutics currently has a consensus price target of $209.14, suggesting a potential upside of 37.88%. Krystal Biotech has a consensus price target of $365.40, suggesting a potential upside of 7.46%. Given Palvella Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Palvella Therapeutics is more favorable than Krystal Biotech.
Summary
Krystal Biotech beats Palvella Therapeutics on 9 of the 15 factors compared between the two stocks.
About Palvella Therapeutics
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
